Lilly says Foundayo cuts predicted 10-year type 2 diabetes risk 57% in ATTAIN-1 post-hoc analysis
LLY•Eli Lilly said post-hoc analyses from its Phase 3 ATTAIN-1 trial linked Foundayo to a 57% reduction in predicted 10-year type 2 diabetes risk versus placebo. The highest dose also pointed to reduced predicted long-term cardiovascular disease risk.
1. Post-hoc findings
Eli Lilly disclosed post-hoc analyses from its Phase 3 ATTAIN-1 trial, with findings published in Diabetes, Obesity and Metabolism. The modeling linked once-daily oral obesity drug Foundayo to lower predicted long-term type 2 diabetes risk versus placebo; the highest dose also pointed to reduced predicted long-term cardiovascular disease risk.
